ALKBH3 suppresses ischemia/reperfusion-induced PANoptosis by regulating the ZBED6/STAT1/AIM2 axis through m¹A demethylation

Abstract

Background: Myocardial ischemia/reperfusion (I/R) injury induces an intense inflammatory response and involves multiple cell death pathways. PANoptosis, an integrated cell death process involving pyroptosis, apoptosis and necroptosis, is a major driver of cardiomyocyte loss during I/R injury. However, the epitranscriptomic control of PANoptosis is poorly understood.

Methods: We investigated the role of ALKBH3, an mRNA N¹-methyladenosine (m¹A) demethylase, in the regulation of cardiomyocyte PANoptosis using hypoxia/reoxygenation models in vitro and murine I/R models in vivo. Integrated transcriptomic and m¹A epitranscriptomic profiling identified downstream targets. Loss- and gain-of-function studies of ALKBH3, AIM2, ZBED6 and STAT1 (siRNA or plasmid overexpression) were coupled with assessments of cell death phenotypes, inflammasome activity and gene expression. Molecular interactions and transcriptional/translational regulation were examined using co-immunoprecipitation, chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays.

Results: Cardiomyocyte-restricted ALKBH3 overexpression mitigates I/R injury in vivo. Mechanistically, ALKBH3 acts as a key suppressor of PANoptosis by inhibiting AIM2. ALKBH3 demethylates m¹A onZBED6 mRNA, enhancing ZBED6 translation and limiting cardiomyocyte PANoptosis. Although ZBED6 does not bind directly to the AIM2 promoter, it physically interacts with STAT1, a transcriptional activator of AIM2, and represses STAT1-driven AIM2 expression. ZBED6 overexpression reduces AIM2 levels and PANoptosis, whereas AIM2 knockout attenuates the exacerbation of cardiac injury and PANoptosis induced by ALKBH3 silencing.

Conclusions: These findings identify the ALKBH3/ZBED6/STAT1/AIM2 signalling axis that epitranscriptomically breaks cardiomyocyte PANoptosis, highlighting a tractable therapeutic target that limits cell death and improves myocardial outcomes after I/R.

Keywords

AIM2 / ALKBH3 / m¹A modification / PANoptosis

References

[1] Sicklinger F, Hartmann N, Kovacs A, et al. High-throughput echocardiography-guided induction of myocardial ischemia/reperfusion in mice. Circ Res. 2025; 136(10): 1099-1109.

[2] Long Q, Rabi K, Cai Y, et al. Identification of splenic IRF7 as a nanotherapy target for tele-conditioning myocardial reperfusion injury. Nat Commun. 2025; 16: 1909.

[3] Hofmann C, Serafin A, Schwerdt OM, et al. Transient inhibition of translation improves cardiac function after ischemia/reperfusion by attenuating the inflammatory response. Circulation. 2024; 150: 1248-1267.

[4] Luo Q, Li Z, Sun W, et al. Myocardia-injected synergistically anti-apoptotic and anti-inflammatory poly(amino acid) hydrogel relieves ischemia-reperfusion injury. Adv Mater. 2025; 37:e2420171.

[5] Chen C, Ma J, Duan S, et al. Mitigation of ischemia/reperfusion injury via selenium nanoparticles: suppression of STAT1 to inhibit cardiomyocyte oxidative stress and inflammation. Biomaterials. 2025; 318:123119.

[6] Lambert JP, Luongo TS, Tomar D, et al. MCUB regulates the molecular composition of the mitochondrial calcium uniporter channel to limit mitochondrial calcium overload during stress. Circulation. 2019; 140: 1720-1733.

[7] Joiner ML, Koval OM, Li J, et al. CaMKII determines mitochondrial stress responses in heart. Nature. 2012; 491: 269-273.

[8] Mendoza A, Patel P, Robichaux D, Ramirez D, Karch J. Inhibition of the mPTP and lipid peroxidation is additively protective against I/R injury. Circ Res. 2024; 134: 1292-1305.

[9] Kirshenbaum LA, Dhingra R, Bravo-Sagua R, Lavandero S. DIAPH1-MFN2 interaction decreases the endoplasmic reticulum-mitochondrial distance and promotes cardiac injury following myocardial ischemia. Nat Commun. 2024; 15: 1469.

[10] Du B, Fu Q, Yang Q, et al. Different types of cell death and their interactions in myocardial ischemia-reperfusion injury. Cell Death Discov. 2025; 11: 87.

[11] Tsurusaki S, Kizana E. Mechanisms and therapeutic potential of multiple forms of cell death in myocardial ischemia-reperfusion injury. Int J Mol Sci. 2024; 25(24):13492.

[12] Mastoor Y, Murphy E, Roman B. Mechanisms of postischemic cardiac death and protection following myocardial injury. J Clin Invest. 2025; 135(1):e184134.

[13] Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024; 23: 130.

[14] Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature. 2016; 530: 441-446.

[15] Deng Y, Chen Z, Chen P, et al. ALKBH3-regulated m(1)A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells. Acta Pharm Sin B. 2025; 15: 3092-3106.

[16] Tu L, Gu S, Xu R, et al. ALKBH3-mediated M(1)A demethylation of METTL3 endows pathological fibrosis:interplay between M(1)A and M(6)A RNA methylation. Adv Sci (Weinh). 2025; 12(19):e2417067.

[17] Sun H, Li K, Liu C, Yi C. Regulation and functions of non-m(6)A mRNA modifications. Nat Rev Mol Cell Biol. 2023; 24: 714-731.

[18] Gu X, Zhuang A, Yu J, et al. Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A. Nucleic Acids Res. 2024; 52: 2273-2289.

[19] Safra M, Sas-Chen A, Nir R, et al. The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017; 551: 251-255.

[20] Smoczynski J, Yared MJ, Meynier V, Barraud P, Tisne C. Advances in the structural and functional understanding of m(1)A RNA modification. Acc Chem Res. 2024; 57: 429-438.

[21] Wang X, Ma X, Chen S, et al. Harnessing m1A modification: a new frontier in cancer immunotherapy. Front Immunol. 2024; 15:1517604.

[22] Wang H, Xie L, Guo H, et al. m(1)A demethylase Alkbh3 regulates neurogenesis through m(1)A demethylation of Mmp15 mRNA. Cell Biosci. 2024; 14: 92.

[23] Ding YP, Liu CC, Yu KD. RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond. Exp Hematol Oncol. 2025; 14: 48.

[24] Cui L, Ma R, Cai J, et al. RNA modifications: importance in immune cell biology and related diseases. Signal Transduct Target Ther. 2022; 7: 334.

[25] Wu Y, Zhan S, Xu Y, Gao X. RNA modifications in cardiovascular diseases, the potential therapeutic targets. Life Sci. 2021; 278:119565.

[26] Zhang G, Wang X, Li C, et al. Integrated stress response couples mitochondrial protein translation with oxidative stress control. Circulation. 2021; 144: 1500-1515.

[27] Zhang L, Duan HC, Paduch M, et al. The molecular basis of human ALKBH3 mediated RNA N(1)-methyladenosine (m(1) A) demethylation. Angew Chem Int Ed Engl. 2024; 63:e202313900.

[28] Cheng W, Ma J, Tao Q, et al. Demethylation of m1A assisted degradation of the signal probe for rapid electrochemical detection of ALKBH3 activity with practical applications. Talanta. 2022; 240:123151.

[29] Wu Y, Chen Z, Xie G, et al. RNA m(1)A methylation regulates glycolysis of cancer cells through modulating ATP5D. Proc Natl Acad Sci USA. 2022; 119:e2119038119.

[30] Bei Y, Zhu Y, Zhou J, et al. Inhibition of Hmbox1 promotes cardiomyocyte survival and glucose metabolism through Gck activation in ischemia/reperfusion injury. Circulation. 2024; 150: 848-866.

[31] Qu Z, Pang X, Mei Z, et al. The positive feedback loop of the NAT10/Mybbp1a/p53 axis promotes cardiomyocyte ferroptosis to exacerbate cardiac I/R injury. Redox Biol. 2024; 72:103145.

[32] Zhao M, Zheng Z, Liu J, et al. LGR6 protects against myocardial ischemia-reperfusion injury via suppressing necroptosis. Redox Biol. 2024; 78:103400.

[33] Wang K, Li FH, Zhou LY, et al. HNEAP regulates necroptosis of cardiomyocytes by suppressing the m(5) C methylation of Atf7 mRNA. Adv Sci (Weinh). 2023; 10:e2304329.

[34] Duan Y, Li Q, Wu J, et al. A detrimental role of endothelial S1PR2 in cardiac ischemia-reperfusion injury via modulating mitochondrial dysfunction, NLRP3 inflammasome activation, and pyroptosis. Redox Biol. 2024; 75:103244.

[35] Shi H, Gao Y, Dong Z, et al. GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R injury. Circ Res. 2021; 129: 383-396.

[36] Liu S, Bi Y, Han T, et al. The E3 ubiquitin ligase MARCH2 protects against myocardial ischemia-reperfusion injury through inhibiting pyroptosis via negative regulation of PGAM5/MAVS/NLRP3 axis. Cell Discov. 2024; 10: 24.

[37] Ma XH, Liu JH, Liu CY, et al. ALOX15-launched PUFA-phospholipids peroxidation increases the susceptibility of ferroptosis in ischemia-induced myocardial damage. Signal Transduct Target Ther. 2022; 7: 288.

[38] Cai W, Liu L, Shi X, et al. Alox15/15-HpETE aggravates myocardial ischemia-reperfusion injury by promoting cardiomyocyte ferroptosis. Circulation. 2023; 147: 1444-1460.

[39] Wang Y, Song Y, Xu L, et al. A membrane-targeting aggregation-induced emission probe for monitoring lipid droplet dynamics in ischemia/reperfusion-induced cardiomyocyte ferroptosis. Adv Sci (Weinh). 2024; 11:e2309907.

[40] Zhu L, Liu Y, Wang K, Wang N. Regulated cell death in acute myocardial infarction: molecular mechanisms and therapeutic implications. Ageing Res Rev. 2025; 104:102629.

[41] Zhang X, Tang B, Luo J, et al. Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope. Mol Cancer. 2024; 23: 255.

[42] Sundaram B, Pandian N, Mall R, et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell. 2023; 186: 2783-2801.e2720.

[43] Sundaram B, Pandian N, Kim HJ, et al. NLRC5 senses NAD(+) depletion, forming a PANoptosome and driving PANoptosis and inflammation. Cell. 2024; 187: 4061-4077.e4017.

[44] Li PB, Bai JQ, Jiang WX, Li HH, Li CM. The mechanosensitive Piezo1 channel exacerbates myocardial ischaemia/reperfusion injury by activating caspase-8-mediated PANoptosis. Int Immunopharmacol. 2024; 139:112664.

[45] Cui B, Qi Z, Liu W, Zhang G, Lin D. ZBP1-mediated PANoptosis: a possible novel mechanism underlying the therapeutic effects of penehyclidine hydrochloride on myocardial ischemia-reperfusion injury. Int Immunopharmacol. 2024; 137:112373.

[46] Chen Y, Guan B, Lu J, et al. Gypensapogenin I alleviates PANoptosis, ferroptosis, and oxidative stress in myocardial ischemic-reperfusion injury by targeting the NOX2/AMPK pathway. Front Cell Dev Biol. 2025; 13:1623846.

[47] Lee S, Karki R, Wang Y, Nguyen LN, Kalathur RC, Kanneganti TD. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021; 597: 415-419.

[48] Fidler TP, Xue C, Yalcinkaya M, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021; 592: 296-301.

[49] Wu L, Su J, Cao Y, et al. Dual-targeting nuclear and mitochondrial DNA damage drives immunogenic activation via PANoptosis for synergistic magneto-thermodynamic-chemotherapy. Biomaterials. 2026; 329:123924.

[50] Onodi Z, Ruppert M, Kucsera D, et al. AIM2-driven inflammasome activation in heart failure. Cardiovasc Res. 2021; 117: 2639-2651.

[51] Mao H, Angelini A, Li S, et al. CRAT links cholesterol metabolism to innate immune responses in the heart. Nat Metab. 2023; 5: 1382-1394.

[52] Li X, Xiong X, Wang K, et al. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. Nat Chem Biol. 2016; 12: 311-316.

[53] Christgen S, Zheng M, Kesavardhana S, et al. Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cell Infect Microbiol. 2020; 10: 237.

[54] Wang Z, Yang Y, Yao FT, et al. KLX ameliorates liver cancer progression by mediating ZBP1 transcription and ubiquitination and increasing ZBP1-induced PANoptosis. Acta Pharmacol Sin. 2025; 46: 2282-2295.

[55] Zhang Z, Zhang F, Pang P, et al. Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma. Front Cell Dev Biol. 2023; 11:1210456.

[56] Zhang M, Zhao X, Cai T, Wang F. PANoptosis: potential new targets and therapeutic prospects in digestive diseases. Apoptosis. 2025; 30: 2745-2760.

[57] Upmanyu K, Upadhyay S. Wiring and rewiring PANoptosis: molecular vulnerabilities for targeting inflammatory cell death in human disease. Cytokine Growth Factor Rev. 2025; 86: 1-16.

[58] Pandeya A, Kanneganti TD. Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes. Trends Mol Med. 2024; 30: 74-88.

[59] Lin Q, Cai H, Yu F, et al. AIM2-PANoptosome-driven PANoptosis in hepatic lipid dysregulation induced by beta-HCH and nanoplastics co-exposure. Apoptosis. 2025; 30: 2340-2357.

[60] Bai M, Lei J, Li F, et al. Short-chain chlorinated paraffins may induce ovarian damage in mice via AIM2- and NLRP12-PANoptosome. Environ Sci Technol. 2025; 59: 163-176.

[61] Chen J, Tao Y, Wang Q, et al. AIM2 regulated by JAK3/STAT1 pathway promotes PANoptosis in intestinal barrier dysfunction caused by concomitant radiation and PD-1 blockade. Apoptosis. 2025; 30: 3009-3025.

[62] Wu H, Jiang W, Pang P, et al. m(6)A reader YTHDF1 promotes cardiac fibrosis by enhancing AXL translation. Front Med. 2024; 18: 499-515.

[63] Mohan M, Akula D, Dhillon A, Goyal A, Anindya R. Human RAD51 paralogue RAD51C fosters repair of alkylated DNA by interacting with the ALKBH3 demethylase. Nucleic Acids Res. 2019; 47: 11729-11745.

[64] Monoe Y, Miyamoto S, Jingushi K, et al. Hypoxia regulates tumour characteristic RNA modifications in ovarian cancers. FEBS J. 2023; 290: 2085-2096.

[65] Wu Y, Jiang D, Zhang H, et al. N1-methyladenosine (m1A) regulation associated with the pathogenesis of abdominal aortic aneurysm through YTHDF3 modulating macrophage polarization. Front Cardiovasc Med. 2022; 9:883155.

[66] Liu Y, Zhang S, Gao X, Ru Y, Gu X, Hu X. Research progress of N1-methyladenosine RNA modification in cancer. Cell Commun Signal. 2024; 22: 79.

[67] Duan J, Cao Z, Zhou Z, et al. Mitochondrial dysfunction drives ZBP1-mediated PANoptosis to increase the susceptibility of heart failure with preserved ejection fraction-associated atrial fibrillation. J Adv Res. 2025.

[68] Xie Y, Shen A, Lin H, et al. Tetramethylpyrazine ameliorates 5-fluorouracil-Induced cardiotoxicity by inhibiting PANoptosis and suppressing the p38 MAPK/JNK/ERK signaling pathway. Eur J Pharmacol. 2025; 1006:178180.

[69] Du L, Wang X, Chen S, Guo X. The AIM2 inflammasome: a novel biomarker and target in cardiovascular disease. Pharmacol Res. 2022; 186:106533.

[70] Xu X, Wang Y, Pei K, et al. Shengmai-Yin resists myocardial ischemia reperfusion injury by inhibiting K27 ubiquitination of absent in melanoma 2. J Ethnopharmacol. 2025; 345:119553.

[71] Zhang X, Song S, Huang Z, et al. Z-DNA-binding protein 1 exacerbates myocardial ischemia‒reperfusion injury by inducing noncanonical cardiomyocyte PANoptosis. Signal Transduct Target Ther. 2025; 10: 333.

[72] Liu H, Pan D, Li P, et al. Loss of ZBED6 protects against sepsis-induced muscle atrophy by upregulating DOCK3-mediated RAC1/PI3K/AKT signaling pathway in pigs. Adv Sci (Weinh). 2023; 10:e2302298.

[73] Younis S, Schonke M, Massart J, et al. The ZBED6-IGF2 axis has a major effect on growth of skeletal muscle and internal organs in placental mammals. Proc Natl Acad Sci U S A. 2018; 115: E2048-E2057.

[74] Younis S, Naboulsi R, Wang X, et al. The importance of the ZBED6-IGF2 axis for metabolic regulation in mouse myoblast cells. FASEB J. 2020; 34: 10250-10266.

[75] Lu C, Ma H, Song L, et al. IFN-gammaR/STAT1 signaling in recipient hematopoietic antigen-presenting cells suppresses graft-versus-host disease. J Clin Invest. 2023; 133(3):e125986.

[76] Zeng G, Lian C, Yang P, Zheng M, Ren H, Wang H. E3-ubiquitin ligase TRIM6 aggravates myocardial ischemia/reperfusion injury via promoting STAT1-dependent cardiomyocyte apoptosis. Aging (Albany NY). 2019; 11: 3536-3550.

[77] Shi X, Xu J, Liu L, et al. Deubiquitinase MYSM1 drives myocardial ischemia/reperfusion injury by stabilizing STAT1 in cardiomyocytes. Theranostics. 2025; 15: 1606-1621.

[78] Zhang J, Xu Y, Wei C, et al. Macrophage neogenin deficiency exacerbates myocardial remodeling and inflammation after acute myocardial infarction through JAK1-STAT1 signaling. Cell Mol Life Sci. 2023; 80: 324.

[79] Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021; 184: 149-168.e117.

[80] Sharma BR, Karki R, Rajesh Y, Kanneganti TD. Immune regulator IRF1 contributes to ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome activation and inflammatory cell death (PANoptosis). J Biol Chem. 2023; 299:105141.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.